{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000024","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.624924+00:00","generated_at":"2026-06-15T23:49:09.563988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ligand Q1 revenue $44M beats prior year; raises FY2023 EPS guidance to $4.60-$4.75","bullets":["Total revenue $44.0M, up 21% from $36.5M in Q1 2022; net income $43.6M vs loss $12.9M.","Raised FY2023 guidance: royalties $78-82M (prev $74-78M); diluted EPS $4.60-4.75 (prev $3.30-3.45).","Royalty revenue $17.2M (+28% YoY) driven by Kyprolis and Pelican platform; core Captisol sales $10.6M (+71%).","Sold 3.2M shares of Viking Therapeutics for $43M net proceeds; holds 3.6M VKTX shares as of Mar 31, 2023.","Travere's FILSPARI approved for IgA nephropathy in Feb; Phase 3 FSGS study missed primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000024","json":"https://secwatch.observer/filing/0000886163-23-000024.json","markdown":"https://secwatch.observer/filing/0000886163-23-000024.md","text":"https://secwatch.observer/filing/0000886163-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/0000886163-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/lgnd-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:49:09.563988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66d861f5591b198e7ad6a0c72c50bbaee0058bda","claim":"LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2023 results: revenue $44.0 million, net income $43.6 million, or $2.43 per diluted share. Guidance raised.","evidence_excerpt":"Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. “2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy,\" said","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/0000886163-23-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$44.0 million"},{"label":"Net income","value":"$43.6 million, or $2.43 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}